The Single-Use Bioreactor Systems Market is anticipated to expand at a high CAGR over the forecast period. is projected to register a strong CAGR during the forecast period (2026-2031).
The market for single-use bioreactor systems is growing as biologics, vaccines, biosimilars, and advanced therapies are in high demand. Compared to conventional stainless-steel bioreactors, these systems come with several benefits, such as decreased capital expenditure, less risk of contamination, fast turnaround times, and more production flexibility. Thus, the biopharmaceutical companies and CDMOs are extensively using these systems for clinical as well as commercial production.
The use of single-use bioreactor (SUB) systems has been increasing alongside the continued rapid growth of the biologics, biosimilars, vaccines, and advanced therapies like cell and gene therapies market. Single-use bioreactors with disposable plastic bags are replacing the traditional stainless-steel vessels and have several benefits, e.g., the perpetual risk of cross-contamination is eliminated, there is less need for hefty capital investment, the operations can be completed more quickly, and the process is more flexible. These systems particularly appeal to the new biotechnology companies and contract development and manufacturing organizations (CDMOs) who need production platforms that can be scaled and are cost-efficient.
Also, more businesses are going for modular and flexible manufacturing facilities, and regulatory authorities are increasingly recognizing the acceptability of disposables; these are some of the factors also helping in the market growth. North America and Europe are presently the market leaders owing to their well-established biopharmaceutical production infrastructure and high R&D investments, while Asia-Pacific is experiencing the fastest growth, which is backed by the development of biotech hubs and government schemes. However, issues such as single-use components, supply chain limitations, and environmental sustainability considerations are still the main areas of concern.
Expansion of the Global Biopharmaceutical Industry: A major driver of single-use bioreactor systems is the rapid growth of the biopharmaceutical sector. Flexible, sterile, and scalable manufacturing solutions are needed to handle the increasing development and commercialization of biologics such as monoclonal antibodies, recombinant proteins, vaccines, and advanced therapy medicinal products (ATMPs). Single-use systems are an effective platform to satisfy this increasing production demand without compromising high-quality standards.
Rising Prevalence of Chronic and Rare Diseases: The increasing global burden of cancer, autoimmune disorders, diabetes, and rare genetic diseases is significantly accelerating the demand for biologic treatments. More innovative biologics are making their way into clinical pipelines and getting regulatory approval; at the same time, manufacturers are choosing single-use bioreactors for rapid production to meet the growing patient needs.
Lower Capital and Operational Costs: Single-use bioreactors significantly cut capital expenditure (CAPEX) as they do not require complex stainless-steel infrastructure along with clean-in-place (CIP) and steam-in-place (SIP) systems. Besides, operational expenditure (OPEX) is also lowered because of less water and energy usage, fewer labor hours, and maintenance activities. The above cost advantage is very crucial to small and mid-sized biotechnology companies.
Expansion of Modular and Flexible Manufacturing Facilities: There has been an increasing use of modular and prefabricated biomanufacturing facilities, which is a good fit for single-use technology. These types of equipment permit the accelerated introduction of the systems, the ability to scale them up, and the effective utilization of the manufacturing space.
Environmental and Sustainability Concerns: One of the major constraints on the single-use bioreactor market is the negative impact on nature caused by its disposable plastic components. The excessive production of plastic waste from bioprocess bags, tubing, and filters leads to concerns about sustainability. Even though waste-to-energy schemes and recycling measures are being developed, it is quite likely that local environmental policies and companies' green objectives will put a cap on the uptake in some areas.
Mechanical Strength and Durability Concerns: Disposable bioreactor bags can be more vulnerable to many types of mechanical failures than stainless-steel systems. Continuous innovations of materials have resulted in increased durability of these materials; however, the uncertainties remain in the case of quite stressful process environments.
Regulatory Documentation Requirements: Even though the regulatory acceptance has increased, manufacturers still need to provide thorough validation data for the use of disposable components. The documentation process may be complicated, particularly when changing suppliers or introducing new materials.
Expansion in Emerging Markets: The fast expansion of biotech sectors in the Asia-Pacific, North America, and Middle East regions is opening opportunities for market growth. In fact, these areas prefer single-use systems as they demand less capital investment and therefore, facility deployment is quicker.
April 2025: WuXi Biologics, a major CRDMO (Contract Research, Development and Manufacturing Organization), revealed that they have finished the first commercial project Process Performance Qualification (PPQ) campaign for three sets of 5, 000L single-use bioreactors (SUBs) used in the second drug substance line of their MFG20 facility at the Hangzhou site.
March 2025: ABEC, which provides engineered solutions and services for biotech manufacturing, has launched the advanced therapy single-use bioreactor (ATB™), a platform that will bring change in cell expansion for Advanced Therapy Medicinal Products (ATMPs). The ATB™ is a newly designed system that can overcome the disadvantages of the existing systems. It has been engineered to give the user complete process control and scalable facilities from bench to commercial scale.
By Product Type– Consumables & Accessories
The Consumables & Accessories segment is one of the rapidly increasing product categories in the single-use bioreactor market. With bioprocessing operations progressively embracing disposable technologies, there is a growing demand for the related consumables such as single-use bags, tubing sets, connectors, filters, and sterile fluid handling components. These products are changed quite often, both between batches and production campaigns, which is why they are a major source of recurring revenue for suppliers.
By Bioreactor Type– Stirred-Tank Single-Use Bioreactors
Stirred-Tank Single-Use Bioreactors account for the strongest growth among different types of bioreactors because they can be used widely across research, clinical, and commercial production. Such bioreactors provide excellent control of critical process parameters, e.g., dissolved oxygen, pH, and mixing efficiency, and they are used extensively for mammalian, bacterial, and yeast cell cultures. Their adaptability makes it possible to go directly from development into manufacturing, which is a significant factor for biopharmaceutical companies that want to shorten their timelines and increase process reproducibility.
By End-User– Contract Development and Manufacturing Organizations (CDMOs)
The Contract Development and Manufacturing Organizations (CDMOs) segment is among the fastest-growing end-user segments in the single-use bioreactor systems market. CDMOs accommodate various biopharmaceutical clients by multi-product production in the same facility. Single-use bioreactor systems are highly compatible with this situation as they not only reduce cleaning validation but also changeover times, thereby reducing the risk of cross-contamination between different production campaigns. Outsourcing pharmaceutical companies are increasingly focused on their core R&D activities, and they are leveraging CDMOs for manufacturing scalability, which is one of the factors that pushes up adoption.
North America has the largest share in single-use bioreactor systems market. Besides a well-established biopharmaceutical manufacturing base, the region is also characterized by strong R&D investments and early adoption of advanced bioprocessing technologies. The United States is at the forefront of the region because of the existence of major biologics manufacturers, biotechnology startups, and Contract Development and Manufacturing Organizations (CDMOs). High demand for monoclonal antibodies, cell and gene therapies, and vaccines supports the adoption of flexible manufacturing systems. Moreover, favorable regulatory frameworks and rising investments in modular and continuous bioprocessing facilities contribute to the strengthening of the regional market growth.
The South American single-use bioreactor systems market is seeing consistent growth. The development of biopharmaceutical manufacturing capabilities and increased local emphasis on producing biologics and vaccines for self-consumption are the main drivers. Brazil holds the leading position in the regional market because of its comparatively developed pharmaceutical infrastructure, the presence of major public health manufacturing institutions, and an increasing focus on biotechnology by the government. Argentina and Colombia are likewise coming up as noteworthy players in the market, backed by enhanced regulatory conditions and increased spending on healthcare.
Europe accounts for a significant portion of the world market, which is reflected by its strong biologics production capabilities and the presence of high regulatory standards. Germany, Switzerland, Ireland, and the United Kingdom play a major role due to their advanced pharmaceutical manufacturing infrastructure. In the region, there is a surge in the use of single-use systems for biologics production at both clinical and commercial scales. On top of that, the rising emphasis on environmentally friendly manufacturing and the rational use of resources is driving the transition to disposable bioprocessing technologies.
The Middle East & Africa region is growing, mainly through increased healthcare investments and government initiatives focused on local pharmaceutical production. The UAE, Saudi Arabia, and South Africa, for instance, are investing their money into biotechnology infrastructure and manufacturing technologies. The rising demand for modular and flexible production facilities is creating a future for the single-use bioreactor systems market in the region.
The single-use bioreactor systems market is growing at the fastest pace in the Asia-Pacific. This is mainly due to the rapid growth of the biotechnology industries in China, India, South Korea, Singapore, and Japan, which is pushing up the demand for cost-effective and scalable manufacturing solutions. To reduce import dependency, the governments across the region are investing heavily not only in healthcare infrastructure but also in local biologics production. The increasing presence of global CDMOs and the resultant rise in outsourcing activities are also aiding the regional growth. Single-use systems are especially attractive in emerging Asian markets because of lower capital requirements and the possibility of faster facility setup.
Sartorius AG
Thermo Fisher Scientific Inc.
Danaher Corporation
Eppendorf AG
Getinge AB
PBS Biotech, Inc.
Distek, Inc.
ABEC, Inc.
Cellexus Ltd.
Celltainer Biotech BV
Infors AG
Thermo Fisher Scientific Inc. is one of the leading global providers of scientific instruments, reagents, and services. They have a presence in the bioprocessing and single-use bioreactor market. Located in Waltham, Massachusetts, USA, the company supplies a wide range of single-use bioreactors, disposable bags, sensors, and other equipment that can be used for biologics development and production at research, pilot, and commercial levels. Thermo Fisher's single-use systems enable biopharmaceutical companies to increase their productivity and shorten turnaround times.
Sartorius AG is a major player in the field of biotechnology worldwide, and it is in Göttingen, Germany. The company offers an extensive range of bioprocessing solutions, including single-use bioreactor systems. The company is engaged in the development and production of disposable bioreactor platforms, consumables, and integrated bioprocess technologies that facilitate the research, development, and commercial production of biologics, vaccines, and advanced therapies. Products of Sartorius in the single-use sector have been successful in laboratories, pilot plants, and large-scale manufacturing facilities because of their scalability and the possibility of simplifying the workflow by minimizing the steps of cleaning and sterilization.